Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Print Print
Recommend this article Recommend this article
Save as favorites Save as favorites
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates


Journal of the American Academy of Dermatology
Volume 48, n° 4
pages 535-541 (avril 2003)
Doi : 10.1067/mjd.2003.143
Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: A double-blind, randomized, placebo-controlled trial*
 

Eugene Monroe, MDa, Albert Finn, MDb, Piyush Patel, MDc, Robinson Guerrero, MDd, Paul Ratner, MDe, David Bernstein, MD

Desloratadine Urticaria Study Group

Milwaukee, Wisconsin; Charleston, South Carolina; Mississauga, Ontario, Canada; Providencia-Santiago, Chile; San Antonio, Texas; and Cincinnati, Ohio 
From Advanced Healthcare, Milwaukeea; National Allergy, Asthma and Urticaria Center of Charlestonb; Medical Director, Allied Clinical Research, Mississaugac; Centro de Enfermedades Respiratorias y Dermatologicas, Providencia-Santiagod; Sylvana Research, San Antonioe; and Bernstein Allergy Group, Cincinnati.f 

Abstract

Background: Chronic idiopathic urticaria (CIU) has a major impact on patient well-being. Antihistamines are the first-line treatment for CIU; however, some cause sedation. Objective: Our purpose was to study the efficacy and safety of desloratadine, 5 mg, a new H1 -receptor antagonist, in patients with moderate to severe CIU. Methods: This study was a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial of 6 weeks' duration. Results: Compared with placebo, desloratadine significantly improved the total CIU symptom score as well as pruritus, the number of hives, and the size of the largest hive. Overall therapeutic response and global CIU status improved significantly with desloratadine; interference with sleep was reduced and the performance of daily activities improved. Statistically and clinically significant improvements were seen within the first 24 hours of treatment and were sustained throughout the full duration of the study. The incidence of adverse events, including somnolence, was similar in the desloratadine and placebo groups. Conclusion: Desloratadine is a well-tolerated and effective treatment of CIU. (J Am Acad Dermatol 2003;48:535-41.)

The full text of this article is available in PDF format.
OutlineMasquer le plan
Methods  (+)
Results  (+)
Discussion

 *A list of all investigators and their sites is given at the end of the article.
 Supported by a grant from Schering-Plough Research Institute.
 Conflict of interest: None identified.
 Reprint requests: Eugene W. Monroe, MD, Advanced Healthcare, Milwaukee Medical Clinic, 3003 W Good Hope Rd, Milwaukee, WI 53209-0996. E-mail: emonroe@ah.com.
♢ 0190-9622/2003/$30.00 + 0



© 2003  American Academy of Dermatology, Inc. Published by Elsevier Masson SAS@@#104157@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline